A review of quality of life in Alzheimer's disease. Parts 1 and 2: Issues in assessing disease impact and drug effects

Comment

M Greer et al. Pharmacoeconomics. 1999 Jun.

. 1999 Jun;15(6):641-4.

doi: 10.2165/00019053-199915060-00009.

No abstract available

Comment in

A review of quality of life in Alzheimer's disease. Parts 1 and 2: Issues in assessing disease impact and drug effects.
McKenna SP, Doward LC. McKenna SP, et al. Pharmacoeconomics. 1999 Oct;16(4):417-9. doi: 10.2165/00019053-199916040-00009. Pharmacoeconomics. 1999. PMID: 10623369 No abstract available.

A review of quality of life in Alzheimer's disease. Part 1: Issues in assessing disease impact.
Walker MD, Salek SS, Bayer AJ. Walker MD, et al. Pharmacoeconomics. 1998 Nov;14(5):499-530. doi: 10.2165/00019053-199814050-00004. Pharmacoeconomics. 1998. PMID: 10344915
A review of quality of life in Alzheimer's disease. Part 2: Issues in assessing drug effects.
Salek SS, Walker MD, Bayer AJ. Salek SS, et al. Pharmacoeconomics. 1998 Dec;14(6):613-27. doi: 10.2165/00019053-199814060-00003. Pharmacoeconomics. 1998. PMID: 10346414